Pirtobrutinib maintenance after car-t therapy for b-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether taking a pill called pirtobrutinib after CAR-T therapy can help keep your lymphoma from coming back. If you've already had CAR-T, this might offer extra protection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a type of large B-cell lymphoma (such as diffuse large B-cell lymphoma or transformed follicular lymphoma).
- You must have already received CAR-T cell therapy (a treatment that uses your own immune cells) and be between 28 days and several weeks after that infusion.
- Any side effects from your past cancer treatments must have mostly gone away or be mild (grade 1 or lower).
- You must be well enough to do light daily activities (ECOG performance status of 0 to 2).
- You cannot have had a stem cell transplant in the past, and you cannot have active serious infections like HIV, hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if taking zanubrutinib (a pill) after CAR-T cell therapy helps keep non-Hodgkin B-cell lymphoma from coming back. It is for people who have already had or will have CAR-T treatment and can continue with this oral medication as a maintenance step.
This trial combines a new type of CAR T-cell therapy (LV20.19) with a targeted pill called pirtobrutinib to treat B-cell lymphomas that have come back or stopped responding. The goal is to see if this combination works better than each alone.
This study tests whether adding a type of maintenance therapy after CAR-T cell treatment helps people with low-risk B-cell lymphoma that has returned or not responded to standard treatments. It compares the standard CAR-T approach to one with extra immune-supporting treatment.
This study tests a new drug, pirtobrutinib, for people with certain types of B-cell lymphoma who have already tried a similar drug (called a BTK inhibitor) and it stopped working or caused side effects. The goal is to see how well it works in real life.
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
This trial studies acalabrutinib given after certain lymphoma treatments (like stem cell transplant or CAR T therapy) to help keep the lymphoma from coming back. It’s for people whose disease has shrunk (partial response) or fully gone away (complete response) after those treatments.
Hear when a new Relapsed or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.